Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h

被引:14
作者
Howden, CW
Metz, DC
Hunt, B
Vakily, M
Kukulka, M
Amer, F
Samra, N
机构
[1] Northwestern Univ, Div Gastroenterol, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Univ Penn, Hlth Syst, Div Gastroenterol, Philadelphia, PA 19104 USA
[3] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
关键词
D O I
10.1111/j.1365-2036.2006.02849.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Attainment of intragastric pH < 6.0 may require high-dose continuously infused proton pump therapy. Aim To assess the pharmacokinetic and pharmacodynamic dose-responses of continuous infusion regimens of lansoprazole. Methods Healthy adult subjects were assigned to lansoprazole 60-mg intravenous bolus, followed by 6-mg/h continuous infusion; a 90-mg intravenous bolus followed by 6-, 7.5-, or 9-mg/h continuous infusion; or placebo. Results Mean intragastric pH values for lansoprazole regimens ranged from 4.8 to 5.2 (0-24 h), 5.5 to 6.0 (> 24 to 48 h) and 5.2 to 5.6 (0-48 h). Within these three intervals, the percentages of time intragastric pH exceeded 4, 5 and 6 ranged from 65% to 96%, 54% to 88% and 30% to 61% respectively. Pharmacokinetic parameters were dose-independent with steady-state plasma concentrations achieved within 6-12 h postdose and maintained over 48 h. The mean systemic clearance of lansoprazole was lower in CYP2C19 heterozygous metabolizers than in homozygous extensive metabolizers (9.2 vs. 16.5 L/h), with substantial variability resulting in overlapping ranges of clearance values for both subpopulations. All lansoprazole regimens were well-tolerated. Conclusions Lansoprazole administered as a 60-mg intravenous bolus followed by 6-mg/h continuous infusion produced intragastric pH effects comparable with those of higher dosage regimens.
引用
收藏
页码:975 / 984
页数:10
相关论文
共 20 条
[1]   Proton-pump inhibitors and outcome of endoscopic Hemostasis in bleeding peptic ulcers: A series of meta-analyses [J].
Andriulli, A ;
Annese, V ;
Caruso, N ;
Pilotto, A ;
Accadia, L ;
Niro, AG ;
Quitadamo, T ;
Merla, A ;
Fiorella, S ;
Leandro, G .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (01) :207-219
[2]  
Barkun A, 2004, GASTROENTEROLOGY, V126, pA78
[3]   High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis [J].
Barkun, AN ;
Herba, K ;
Adam, V ;
Kennedy, W ;
Fallone, CA ;
Bardou, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (05) :591-600
[4]  
Brunner G, 1996, YALE J BIOL MED, V69, P225
[5]   INTRAVENOUS THERAPY WITH HIGH-DOSES OF RANITIDINE AND OMEPRAZOLE IN CRITICALLY ILL PATIENTS WITH BLEEDING PEPTIC ULCERATIONS OF THE UPPER INTESTINAL-TRACT - AN OPEN RANDOMIZED CONTROLLED TRIAL [J].
BRUNNER, G ;
CHANG, J .
DIGESTION, 1990, 45 (04) :217-225
[6]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[7]   Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers - Randomized double-blind placebo-controlled multicentre study [J].
DeMuckadell, OBS ;
Havelund, T ;
Harling, H ;
Boesby, S ;
Snel, P ;
Vreeburg, EM ;
Eriksson, S ;
Fernstrom, P ;
Hasselgren, G .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (04) :320-327
[8]   Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding - Results of a placebo-controlled multicenter study [J].
Hasselgren, G ;
Lind, T ;
Lundell, L ;
Aadland, E ;
Efskind, P ;
Falk, A ;
Hyltander, A ;
Soderlund, C ;
Eriksson, S ;
Fernstrom, P .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (04) :328-333
[9]   Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer [J].
Javid, G ;
Masoodi, I ;
Zargar, SA ;
Khan, BA ;
Yatoo, GN ;
Shah, AH ;
Gulzar, GM ;
Sodhi, JS .
AMERICAN JOURNAL OF MEDICINE, 2001, 111 (04) :280-284
[10]   Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial [J].
Kaviani, MJ ;
Hashemi, MR ;
Kazemifar, AR ;
Roozitalab, S ;
Mostaghni, AA ;
Merat, S ;
Alizadeh-Naini, M ;
Yarmohammadi, H .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (02) :211-216